Citation: | ZHANG Jinlin, YUAN Yaozuo, ZHANG Ya, ZHAO Shuqiang, ZHAO Xun, ZHANG Mei. Consistency evaluation of domestic generic rifampicin capsules and reference drug in vitro[J]. Journal of China Pharmaceutical University, 2018, 49(5): 603-609. DOI: 10.11665/j.issn.1000-5048.20180513 |
[1] |
Duan ZH.Research progress of isoniazid and rifampicin on liver toxicity[J].J Mod Med(现代医学),2013,41(6):430-433.
|
[2] |
Chinese Pharmacopeia Commission.Chinese Pharmacopeia:part 2(中华人民共和国药典:二部)[S].Beijing:China Medical Science Press,2015:498-499.
|
[3] |
The United States Pharmacopieial Convention.The United States Pharmacopeia[S].40th ed.Baltimore:United Book Press,2017:6007-6009.
|
[4] |
The British Pharmacopieial Commission.The British Pharmacopeia[S].London:The Stationery Office,2015:1058-1059.
|
[5] |
Japanese Pharmacopoeia Commission.The Japanese Pharmacopeia[S].17th ed.Tokyo:Pharmaceutical and Medical Device Regulatory Science Society of Japan,2017:1518-1520.
|
[6] |
European Pharmacopoeia Commission.European Pharmacopeia 9.0:volume Ⅱ[S].France:European Directorate for the Quality of Medicines & HealthCare,2017:3489-3490.
|
[7] |
Yu QH.Consistency evaluation of generic drug in our country and original drug[J].Shanghai Med Pharm J(上海医药),2013,34(5):35-37.
|
[8] |
Becker C,Dressman JB,Junqinqer HE,et al.Biowaiver monographs for immediate release solid oral dosage forms:rifampicin[J].J Pharm Sci,2009,98(7):2252-2267.
|